Conclusions
TRD, depression
In this RCT of simvastatin added to standard care in the short-term treatment of TRD, adjunctive simvastatin provided no therapeutic benefit compared with placebo added to standard care. Further research is needed to identify immune-metabolic phenotypes of depression that may be more responsive to, or preventable with, targeted statins or other immunomodulatory treatments.